Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Open accessAbstract
AIMS: Aim of the present study was to evaluate the impact of once-weekly semaglutide on different end-points indicative of metabolic control, cardiovascular risk, dietary behavior, and treatment satisfaction in T2DM. METHODS: This was a retrospective observational study conducted in a diabetes clinic. Changes in HbA1c, fasting blood glucose (FBG), weight, blood pressure, lipid profile, and number of antihypertensive drugs at 32 weeks (T1) after the first prescription of semaglutide (T0) were analyzed. Furthermore, at T1 patients were asked to fill-in the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Control of Eating Questionnaire (COEQ). RESULTS: Overall, 104 patients were identified (mean age 63.6 ± 10.4 years, 58.7% men, diabetes duration 12.7 ± 8.7 years). After 32 weeks of treatment with semaglutide, HbA1c levels were reduced by 1.38%, FBG by - 56.53 mg/dl, weight by 6.03 kg. Systolic and diastolic blood pressure, total, HDL-, LDL-, and non -HDL cholesterol, and triglycerides significantly improved. The number of glucose-lowering and antihypertensive drugs also decreased. At T1, DTSQ score was 32.23 ± 1.44, whereas COEQ indicated low levels of hunger and good control of eating. CONCLUSIONS: The study documented benefits of semaglutide on metabolic control and multiple CV risk factors, simplification of therapeutic schemes and high satisfaction with diabetes treatment, and eating behaviors indicative of healthy diet and reduced food intake.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HDL levels might improve with a longer duration of treatment.
“HDL levels, despite showing overall absolute improvements, did not reach statistical significance, suggesting this variable might improve with a longer duration of treatment.40”
From The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients (2026) · cites this paper as [40]
The Results (Table 2; page unavailable) report that HDL cholesterol increased significantly after 32 weeks of semaglutide treatment (p = 0.0006). This contradicts the citing sentence’s premise that the improvement did not reach statistical significance; the paper does not present a longer treatment duration as necessary for HDL improvement. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 38 · Cited by 29
Research works printed but not linked: 1
- [18]Blundell J Finlayson G Axelsen M Flint A Gibbons C Kvist T Hjerpsted JB Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Diabetes Obes Metab 2017 19 1242 1251 10.1111/dom.12932 28266779 PMC5573908 · DOI · Paper page
- Authors
- Di Folco, U., Vallecorsa, N., Nardone, M. R., Pantano, A. L., & Tubili, C.
- Affiliations
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- ORCID
- Di Folco, Ugo
- Venue
- Acta Diabetologica
- Published
- 2022-07-17
- Volume
- 59
- Issue
- 10
- Pages
- 1287-1294
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- PMC
- PMC9288662
- OpenAlex
- W4285677322
- Cited by
- 29
- References
- 38
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 7 · 2023: 6 · 2022: 1
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Acta Diabetologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, type 2 diabetes, cardiovascular risk factors, glycemic control, dietary habits, treatment satisfaction, weight loss, lipid profile, blood pressure, antihypertensive drugs, GLP-1 receptor agonists, hunger
- MeSH terms
- Heart Disease Risk Factors, Semaglutide, Aged, Antihypertensive Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Feeding Behavior, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Risk Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
